Education and Training
Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease
Specific Aim 1: Characterize the effects of vitamin D treatment on expression of α4β7 on B cells in patients with inflammatory bowel disease (IBD).
Specific Aim 2: Determine the effects of vitamin D treatment on fecal immunoglobulins, percentage of Ig-coated gut bacteria, gut microbiome composition (global and bound by immunoglobulins) in patients with IBD and the association of these parameters with change in α4β7+ B cells .
Specific Aim 3: Compare BCR repertoire (BCR clonotypes, immunoglobulin heavy chain gene (IGHV), and isotype usage) between α4β7+ and α4β7- B cells in patients with IBD and identify α4β7+ BCR clonotypes associated with Ig-bound gut bacteria .
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Vitamin D
Eligibility
Inclusion Criteria:
- Adult patients (18 years or older) with inflammatory bowel disease (ulcerative colitis
or Crohn's disease)
- Low serum vitamin D (25(OH)D ≤ 25 ng/mL
- Not currently on high dose vitamin D supplementation
- No prior bowel resections
- No antibiotic use in past 3 months.
Exclusion Criteria:
- Patients less than 18 years old
- No diagnosis of IBD
- Serum 25(OH)D > 25 ng/mL
- Patients already on vitamin D supplementation
- Prior history of bowel surgery (colectomy or small bowel resections)
- Recent antibiotic use in past 3 months
- Renal Dysfunction
- History of Hypercalcemia
- History of HIV
- History of IgA deficiency
- History of Common Variable Immunodeficiency (CVID)
- Active C. diff infection
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
John Gubatan, MD
650-725-3362
Not Recruiting